Rare Bleeding Disorders
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Medical Information
    Non-US Health Care Professionals
Rebinyn® coagulation factor IX (recombinant), glycoPEGylated logo
Important Safety Information | Patient Site
Prescribing Information
    • How it Works
    • Patient Use Cases
    • Efficacy
    • Safety Profile
    • Pharmacokinetics
    • FIX PK Comparisons
    • Comparative Modeling
    • Simplified Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
Rebinyn® coagulation factor IX (recombinant), glycoPEGylated logo

Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes and perioperative management of bleeding.

Prescribing Information
Important Safety Information | Patient Site

Rebinyn® is the only factor IX with simplified dosing

Unlike other FIX products, with Rebinyn® there’s no need to calculate desired FIX activity levels when determining the appropriate dose.1-6

Rebinyn® is the only factor IX with simplified dosing

Unlike other FIX products, with Rebinyn® there’s no need to calculate desired FIX activity levels when determining the appropriate dose.1-6


Clayton

The recommended dose for all patients is:

40 IU/kg

for minor or moderate bleeds1,a
80 IU/kg for major bleeds1,a

Minor to moderate bleeds can usually be treated with a single 40 IU/kg dose.a For major bleeds, doses can be increased to 80 IU/kg.a

aA single dose should be sufficient for minor and moderate bleeds. Additional doses of 40 IU/kg can be given.

Dosing for perioperative management1

Type of Surgical Procedure

Recommended dose

Additional information

Type of Surgical Procedure

Minor
For example: Implanting pumps in subcutaneous tissue, skin biopsies or simple dental procedures.

Recommended dose

40 IU/kg1,b

Additional information

A single pre-operative dose should be sufficient. Additional doses can be given if needed.

Type of Surgical Procedure

Major
For example: Body cavity is entered, mesenchymal barrier is crossed, fascial plane is opened, organ is removed, normal anatomy is operatively altered.

Recommended dose

80 IU/kg1,c

Additional information

Pre-operative dose.


Recommended dose

40 IU/kg1,d

Additional information

As clinically needed for the perioperative management of bleeding, repeated doses of 40 IU/kg (in 1-3 day intervals) within the first week after major surgery may be administered. 
Due to the long half-life of Rebinyn®, the frequency of dosing in the post-surgical setting may be extended to once weekly after the first week until bleeding stops and healing is achieved.

bA single pre-operative dose should be sufficient. Additional doses of 40 IU/kg can be given.

cPre-operative dose. Repeated doses of 40 IU/kg (in 1–3 day intervals) within the first week after major surgery may be administered.

dPlease see Prescribing Information for complete instructions.

Select features of FIX products1-6

Factor IX product feature comparison
Factor IX product feature comparison

As of November 2021, Rebinyn® is not approved for routine prophylaxis.

The above table does not imply that one FIX product is more effective than another product.

Flexible storage for patients on-the-go

Rebinyn® does not require refrigeration. It can be stored at room temperature (up to 86˚F) for up to 6 months, and for up to 4 hours after reconstitution.

Requires no refrigeration up to 86˚F.1

Room temperature stable


for up to 6 months

Post-reconstitution storage


for up to 4 hours

If you choose to store Rebinyn® at room temperature, do not return it to the refrigerator. Rebinyn® vials can also be stored in the refrigerator at 36˚F–46˚F for up to 24 months or until the expiration date stated on the label. Please see Prescribing Information for complete storage instructions.

Factor IX monitoring icon

Factor IX monitoring

Factor IX activity assay results may be significantly affected by the type of aPTT reagent, which can result in over- or under-estimation of FIX activity. Rebinyn® FIX activity levels and inhibitor testing is available through the Novo Nordisk Lab Program, using validated assays in compliance with CAP/CLIA regulations.

To activate your Labcorp account and participate in the program, download and complete the form, then email it to fixsupport@labcorp.com.

What does Rebinyn® offer patients like Chris?

Chris is 31, lives with moderate hemophilia B and leads a busy lifestyle—including frequent travel for work. Explore the features of Rebinyn® that may make it an appropriate factor IX therapy for him.

See patient case examples
Chris patient profile

For illustrative purposes.


Rebinyn® Lab Program Form
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® Lab Program Form
Download this form to activate a Labcorp account and participate in the Novo Nordisk Lab Program. Email the completed form to fixsupport@labcorp.com.
Download
Prescribing Information | Important Safety Information

Please see Prescribing Information for complete monitoring information.


Multiple vial sizes

Rebinyn® vials

Rebinyn® is available as a white lyophilized powder in single-use vials. Color-coded vial caps differentiate the dose strengths.1

Established safety profile

Clinical trials showed 0 inhibitors and thrombotic events in previously treated patients.1 

View the data

Rebinyn® trial prescription program

Rebinyn Box

Considering Rebinyn® for your patients with hemophilia B?

To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.

Selected Important Safety Information for Rebinyn®

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic type reactions occur and initiate appropriate treatment.

Indications and Usage

Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes and perioperative management of bleeding.

Limitations of Use: Rebinyn® is not indicated for routine prophylaxis or for immune tolerance induction in patients with hemophilia B.

Important Safety Information

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic-type reactions occur and initiate appropriate treatment.
  • Development of neutralizing antibodies (inhibitors) to Factor IX may occur. Monitor patients for development of factor IX inhibitors if bleeding is not controlled with the recommended dose of Rebinyn® or if expected Factor IX activity plasma levels are not attained. Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used.
  • The use of Factor IX-containing products has been associated with thrombotic complications. Monitor for thrombotic and consumptive coagulopathy when administering Rebinyn® to patients with liver disease, post-operatively, to newborn infants, or to patients at risk of thrombosis or disseminated intravascular coagulation (DIC).
  • Nephrotic syndrome has been reported following immune tolerance induction therapy with Factor IX products in hemophilia B patients with Factor IX inhibitors, often with a history of allergic reactions to Factor IX. The safety and efficacy of using Rebinyn® for immune tolerance induction have not been established.

Adverse Reactions

  • The most common adverse reactions reported in clinical trials (≥1%) were itching and injection site reactions.
  • Animals administered repeat doses of Rebinyn® showed accumulation of PEG in the choroid plexus. The potential clinical implications of these animal findings are unknown.

Please click here for Rebinyn® Prescribing Information.

Reference:

  1. Rebinyn [package insert]. Plainsboro, NJ: Novo Nordisk Inc; June 2020. 
  2. Benefix [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2021. 
  3. Alprolix [package insert]. Cambridge, MA: Biogen Inc; 2018. 
  4. Idelvion [package insert]. Kankakee, IL: CSL Behring LLC; 2020. 
  5. Ixinity [package insert]. Berwyn, PA: Aptevo BioTherapeutics LLC; 2021.
  6. Rixubis [package insert]. Westlake Village, CA: Baxalta Healthcare Corporation; 2020.
Rare Bleeding Disorders
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

Rebinyn® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2021 Novo Nordisk All rights reserved.  US21REB00006 November 2021

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials